Latest news with #JenniferSchneider
Business Wire
5 days ago
- Business
- Business Wire
Homeward and Meijer Launch Rural Health Partnership to Expand Care Access for Michiganders
SAN MATEO, Calif. & GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- Homeward®, a technology-enabled rural health platform dedicated to expanding access to quality healthcare in rural America, today announced a strategic partnership with Meijer, a privately owned, family-operated Midwest retailer, to improve healthcare access and care coordination for Medicare-eligible residents across the state. Rural Michiganders face significant health and economic disparities compared to those living in urban areas, with lower median household incomes, fewer primary care providers, and higher rates of chronic conditions like diabetes. The lack of reliable broadband access may limit their ability to participate in virtual care, while higher levels of food insecurity and reduced access to specialized services underscore the need for improved healthcare solutions in rural communities. To address these needs, Homeward and Meijer are partnering to make healthcare more accessible for seniors across Michigan. Through this partnership, eligible Meijer pharmacy customers will gain access to comprehensive health management support, including help with coordinating preventive care, simplifying medication access, and addressing social factors that impact their overall well-being. The Homeward Navigation™ platform will leverage advanced analytics to connect eligible seniors to the right care and local resources, with the goal of effectively addressing social determinants of health and improving holistic health outcomes. Research shows Medicare beneficiaries visit the pharmacy nearly twice as often as they visit their primary care physician, building on research supporting the benefits of integrating pharmacists into care teams. With Homeward members in Michigan already frequenting Meijer pharmacies, the partnership leverages Meijer's strong presence across the state, particularly in rural areas, to make healthcare more accessible. In addition to Meijer's established footprint in rural counties of the Upper Peninsula, all 43 Lower Peninsula counties served by Homeward have a Meijer pharmacy either within the county or in an adjacent county. 'We are proud to partner with Meijer, a trusted, family-owned retailer deeply rooted in the communities we serve. Grocers and pharmacies are among the most frequented and trusted places in rural areas, and our partnership will make care delivery and support more convenient and accessible across rural Michigan,' said Co-Founder and CEO of Homeward, Dr. Jennifer Schneider. 'This partnership underscores Homeward's commitment to meeting the unique needs of each community by building tailored care models that make it easier for people to access the quality care they need to get and stay healthy.' By meeting people where they live and shop, this collaboration helps bridge critical gaps in care, ensuring rural Michiganders receive the support they need to lead healthier lives. 'At Meijer, we are committed to delivering services and products that enhance the well-being of our customers and communities. This includes rural areas that experience limited access to healthcare and healthy foods,' said Jackie Morse, Group Vice President for Meijer Pharmacy & Health. 'Through our partnership with Homeward, we are enhancing care coordination for rural Michiganders, helping them navigate healthcare services, access the support they need, and address key social determinants of health. By fostering better collaboration between patients and healthcare providers, this partnership ensures patients receive high quality, coordinated care.' For more information about Homeward, its services in Michigan, and eligibility, visit For more information about Meijer and a list of locations, visit About Meijer Meijer is a privately owned, family-operated retailer that serves customers at more than 500 supercenters, grocery stores, neighborhood markets, and express locations throughout the Midwest. As the pioneer of the one-stop shopping concept, more than 70,000 Meijer team members work hard to deliver a friendly, seamless in-store and online shopping experience featuring an assortment of fresh foods, high-quality apparel, household essentials, and health and wellness products and services. Meijer is consistently recognized as a Great Place to Work and annually donates at least 6 percent of its profit to strengthen its communities. Additional information on the company can be found by visiting About Homeward Homeward is rearchitecting rural healthcare by pairing AI-native infrastructure with deeply human services. As the only AI-native platform built specifically for rural populations, we partner with payers and providers to extend clinical capacity, close care gaps, and deliver population-level outcomes at scale—improving health, reducing costs, and restoring trust in care where it's needed most. As a public benefit corporation and B Corp™ certified company, Homeward's mission and business model are aligned to address the healthcare, economic, and demographic challenges that make it harder for rural Americans to stay healthy. For more information, please visit
Yahoo
04-03-2025
- Business
- Yahoo
Centauri Therapeutics Selects First Clinical Candidate, for Immunotherapeutic Treatment of Gram-negative Bacterial Infections
Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients LONDON, March 04, 2025--(BUSINESS WIRE)--Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company's Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. This drug candidate will now be further developed ahead of progression to first in-human clinical studies. The lead candidate in the ABX-01 programme is a broad-spectrum antimicrobial peptide specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Preclinical studies have demonstrated the compound's activity against Gram-negative bacteria. "We are excited to enter the clinical development phase with the ABX-01 lead candidate, thanks to our dedicated team who have worked hard to advance our Alphamer platform to this crucial stage. The platform has the potential to address a vital gap in the current anti-infective treatment landscape, and we remain confident that our lead candidate will continue to demonstrate this as we progress towards a Phase I clinical trial," commented Dr Jennifer Schneider, CEO, Centauri Therapeutics. "We are proud to progress this molecule with the continuous support of our investors and our long-standing partner, CARB-X, for which we are grateful." Dr Helen Bright, CSO, Centauri Therapeutics, said: "Our focus at Centauri Therapeutics has always been on developing novel immune therapy approaches to expand treatment options for the most vulnerable, starting with the anti-infectives space. Reaching this stage highlights the potential of our disruptive technology, not only in anti-infectives, but also within the oncology and vaccines spaces. I look forward to working alongside our brilliant and highly motivated team to take us into this next phase of development." Centauri is now conducting regulatory preclinical activities to enable streamlined progression of its lead clinical candidate into a Phase I clinical trial. Research reported in this press release is supported by CARB-X. CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany's Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. View source version on Contacts Katie Sign in to access your portfolio
